ClinicalTrials.gg
RecruitingNCT07420985Updated Feb 19, 2026

Study to Evaluate the Efficacy, Safety, and Tolerability of the Ingavirin Forte Capsules (Valenta Pharm JSC) at Different Doses in Subjects With Influenza and Other Acute Respiratory Viral Infections.

A Phase 2 interventional study of Ingavirin Forte, 90 mg + 5 mg, Capsules and Ingavirin Forte, 90 mg + 10 mg, Capsules in Influenza and Acute Respiratory Viral Infection, sponsored by Valenta Pharm JSC. Recruiting at 11 sites in Russia. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-19.

Sponsored by Valenta Pharm JSC · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 15 studies in Influenza, Human by Valenta Pharm JSC — 4 open to participants now, 4 under way, none of them phase 3. Influenza, Human · Valenta Pharm JSC.

Planned enrollment
4th of 15
300 · median 240
Started
2025
with 2 others
Phase 2
3 of 15
1 open now
Registered
14th of 15
by date

Among the 15 studies in Influenza, Human by Valenta Pharm JSC, this one is the 4th largest by planned enrollment, is one of 3 that started in 2025, is one of 3 in phase 2, and was the 14th registered.

Influenza, Human

2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

4 of the 15 studies in Influenza, Human by Valenta Pharm JSC are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Influenza, Human by Valenta Pharm JSC, or all of them as a file.
02

Study summary

The objective of this study is to investigate the efficacy, safety, and tolerability of investigational product Ingavirin forte capsules (Valenta Pharm JSC) administered at different doses compared with medicinal product Ingavirin, 90 mg, capsules (Valenta Pharm JSC) in subjects with influenza or other acute respiratory viral infections (ARVIs).

03

Conditions studied

  • Influenza
  • Acute Respiratory Viral Infection

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Voluntarily and personally signed Form (ICF) by a participant obtained prior to the conduct of any study-related procedure;
  2. Males and females aged 18 to 65 years (inclusive) at the time of signing the ICF;
  3. Subjects with influenza or other acute respiratory viral infections confirmed by polymerase chain reaction (PCR);
  4. Presence of signs of influenza or acute respiratory viral infections at screening:

    • Body temperature >38,0 °С at randomization, with no intake NSAID within 12 hours before randomization;
    • Presence of at least two of the following symptoms of influenza or other acute respiratory viral infections (cough, rhinorrhea, sore throat, or a throat irritation) each rated non less than 6 points on a numeric rating scale (NRS);
    • Presence of at least one of the following systemic manifestations of influenza or other acute respiratory viral infections (headache, myalgia, or general weakness) rated non less than 6 points on a numeric rating scale (NRS).
  5. Duration of illness from symptoms onset to administration of the first dose of medical product or comparator is ≤ 48 hours;
  6. No clinical indications for hospitalization at the time of study enrollment;
  7. Consent to use adequate methods throughout the study and for 30 days after study completion. The follwing subjects are eligible for inclusion in the study:

    • Females of must have a negative pregnancy test and use one of the folliwing adequate contraceptive methods: sexual abstinence, condom combined with spermicide or hormonal contraceptives, contraceptive subdermal implant, intrauterine hormonal system, intrauterine device. Females not of childbearing potential (i.e., with a history of hysterectomy, bilateral oophorectomy, bilateral tubal ligation, comfirmed infertility, or ≥ 2 of menopause) are also eligible for participation;
    • Males with reptoductive potential must use one of the folliwing adequate contraceptive methods: sexual abstinence, condom combined with spermicide or hormonal contraceptives. Males with infertility or a history of vasectomy are also eligible for participation;

Exclusion Criteria:

  1. Clinically significant allergic history;
  2. to active substances of medical produtcs Ingavirin and Ingavirin forte, and/or to any contaned in the investigational medicinal product or comparator;
  3. Intolerance to active substances of medical produtcs Ingavirin and Ingavirin forte, and/or to any excipient contaned in the investigational medicinal product or comparator;
  4. Known galactose intolerance, lactase deficiency, or glucose-galactose malabsorption;
  5. Clinical suspicion of pneumonia of any etiology, or other bacterial infection (e.g. sinusitis, otitis media, urinary tract infection, meningitis, sepsis) requiring initiation for antibacterial therapy;
  6. Nasal obstruction due to structural pathology, such as sequelae of nasal trauma, nasal polyps, septal deviation, or other organic causes;
  7. History of vasomotor rhinitis;
  8. Administration of antibiotics, antiviral (including Ingavirin), or immunomodulatory agents within 48 hours prior to study, and/or anticipated need for any of these agents during the study;
  9. Vaccination within 90 days prior to study enrollment;
  10. Uncontrolled diabetes mellitus;
  11. Obesity, class II or III ( ≥35 kg/m²);
  12. Pregnancy or lactation;
  13. Positive test for SARS-CoV-2 at screening;
  14. History of diseases;
  15. Current or past , syphilis, and/or C, or tuberculosis;
  16. Known or suspected history of alcohol, psychotropic drug, or substance abuse or dependence;
  17. History of chronic respiratory disease, including but not limited to: (COPD), asthma, chronic bronchitis, diffuse panbronchiolitis, pulmonary emphysema, or pulmonary fibrosis;
  18. Chronic heart failure, (NYHA) functional class III or IV;
  19. Current or past psychiatric disoder;
  20. Any clinically significant cardiovascular, renal, hepatic, gastrointestinal , endocrine, or neurological disoder, including severe uncompensated chronic conditions (e.g., chronic kidney disease, chronic liver disease) or acute illness, or any other medical or psychiatric condition that, in investigator's opinion, could pose a safety risk to the subject if they participate in the study;
  21. Subject's refusal to use an adequate method of contraception or to practice continuous sexual abstinence throughout the study and for 30 days after study completion;
  22. Participation in another clinical trial within 3 months prior to screening;
  23. Other conditions which, in the judgment of the investigator, could compromise the subject's participation in the study or pose an undue risk.

Exclusion Criteria:

  1. Subject's decision to withdraw from the study (withdrawal of informed consent);
  2. Investigator's decision to discontinue the subject from the study in the subject's best interest;
  3. Investigator-determined need for a concomitant therapy explicitly prohibited by the protocol of clinical study;
  4. Subject's use of a therapy prohibited by the protocol;
  5. Positive urine test for beta-human chorionic gonadotropin (β-hCG) in females of childbearing potential;
  6. Lack of adequate cooperation by the subject with the investigator during the study;
  7. Emergence during the study of conditions or events that jeopardize subject safety (e.g., hypersensitivity reactions, serious adverse events [SAEs]) or, in the investigator's medical judgment, worsen the subject's prognosis or preclude further participation in the clinical study;
  8. Incorrect inclusion of a subject who does not meet the protocol-specified inclusion and/or exclusion criteria;
  9. Major deviation from the treatment regimen, defined as:

    • Missing two or more consecutive doses of the investigational medicinal product (IMP) or comparator;
    • Total intake of fewer than 80% or more than 120% of the planned total number of capsules (full course includes 10 capsules);
  10. Confirmed diagnosis of COVID-19;
  11. Occurrence during the study of any other condition that precludes adherence to the protocol;
  12. Subject's death.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Ingavirin Forte, 90 mg + 5 mg, Capsules

    Subjects will receive Ingavirin Forte, 90 mg + 5 mg, 1 capsule twice daily (morning and evening), for 5 consecutive days.

    Drug: Ingavirin Forte, 90 mg + 5 mg, Capsules

  • Experimental
    Ingavirin Forte, 90 mg + 10 mg, Capsules

    Subjects will receive Ingavirin Forte, 90 mg + 10 mg, 1 capsule twice daily (morning and evening), for 5 consecutive days.

    Drug: Ingavirin Forte, 90 mg + 10 mg, Capsules

  • Experimental
    Ingavirin Forte, 90 mg + 20 mg, Capsules

    Subjects will receive Ingavirin Forte, 90 mg + 20 mg, 1 capsule twice daily (morning and evening), for 5 consecutive days.

    Drug: Ingavirin Forte, 90 mg + 20 mg, Capsules

  • Active comparator
    Ingavirin Forte, 90 mg , Capsules

    Subjects will receive Ingavirin, 90 mg, 1 capsule twice daily (morning and evening), for 5 consecutive days.

    Drug: Ingavirin, 90 mg, Capsules

  • Placebo comparator
    Placebo, Capsules

    Subjects will receive Placebo, 1 capsule twice daily (morning and evening), for 5 consecutive days.

    Drug: Placebo

Interventions

  • DrugIngavirin Forte, 90 mg + 5 mg, Capsules

    90 mg + 5 mg, 1 capsule twice a day, for 5 days

    Also known as: Imidazolyl ethanamide pentandioic acid + N,N'-bis-[2-(1,3-Diazocyclopenta2,4-dien-4-yl)ethyl] diamide of malonic acid

  • DrugIngavirin Forte, 90 mg + 10 mg, Capsules

    90 mg + 10 mg, 1 capsule twice a day, for 5 days

    Also known as: Imidazolyl ethanamide pentandioic acid + N,N'-bis-[2-(1,3-Diazocyclopenta2,4-dien-4-yl)ethyl] diamide of malonic acid

  • DrugIngavirin Forte, 90 mg + 20 mg, Capsules

    90 mg + 20 mg,1 capsule twice a day, for 5 days

    Also known as: Imidazolyl ethanamide pentandioic acid + N,N'-bis-[2-(1,3-Diazocyclopenta2,4-dien-4-yl)ethyl] diamide of malonic acid

  • 90 mg, 1 capsule twice a day, for 5 days

    Also known as: Imidazolyl ethanamide pentandioic acid

  • DrugPlacebo

    1 capsule twice a day, for 5 days

06

What researchers measure

Primary outcomes

  1. Time (in hours) from the first dose of the study drug to the sustained resolution of all the following symptoms/events (with each resolved symptom/event persisting for at least 24 hours without the use of NSAIDs and/or decongestants):

    * fever (the first time point at which body temperature remains stably normalized (\<37.0°C) for 24 h); * runny nose/rhinorrhoea (the first time point with Numeric Rating Scale (NRS) ≤ 2 which maintained for ≥24 h); * nasal congestion/stuffiness (the first time point with NRS ≤ 2 which maintained for ≥24 h); * sore throat (the first time point with NRS ≤ 2 which maintained for ≥24 h); * throat irritation (the first time point with NRS ≤ 2 which maintained for ≥24 h); * cough (the first time point with NRS ≤ 2 which maintained for ≥24 h); * generalized weakness/malaise (the first time point with NRS ≤ 2 which maintained for ≥24 h); * headache (the first time point with NRS ≤ 2 which maintained for ≥24 h); * myalgia (the first time point with NRS ≤ 2 which maintained for ≥24 h).

    Time frame: Day 1 - Day 10 of the study.

Secondary outcomes

  1. Mean daily symptom severity score based on the NRS (arithmetic mean of the scores over a 24-hour period). A "day" will be calculated as 24-hour intervals starting from the time of the first dose administration.

    * fever (arithmetic mean of the daily scores); * runny nose/rhinorrhoea (arithmetic mean of the daily scores); * nasal congestion/stuffiness (arithmetic mean of the daily scores); * sore throat (arithmetic mean of the daily scores); * throat irritation (arithmetic mean of the daily scores); * cough (arithmetic mean of the daily scores); * generalized weakness/malaise (arithmetic mean of the daily scores); * headache (arithmetic mean of the daily scores); * myalgia (arithmetic mean of the daily scores).

    Time frame: Day 1 - Day 10 of the study.

  2. Time (in hours) from first dose of study drug to resolution of disease symptoms.

    * fever (the first time point at which symptom severity remains ≤ 2 on NRS for 24 h); * runny nose/rhinorrhoea (the first time point at which symptom severity remains ≤ 2 on NRS for 24 h); * nasal congestion/stuffiness (the first time point at which symptom severity remains ≤ 2 on NRS for 24 h); * sore throat (the first time point at which symptom severity remains ≤ 2 on NRS for 24 h); * throat irritation (the first time point at which symptom severity remains ≤ 2 on NRS for 24 h); * cough (the first time point at which symptom severity remains ≤ 2 on NRS for 24 h); * generalized weakness/malaise (the first time point at which symptom severity remains ≤ 2 on NRS for 24 h); * headache (the first time point at which symptom severity remains ≤ 2 on NRS for 24 h); * myalgia (the first time point at which symptom severity remains ≤ 2 on NRS for 24 h).

    Time frame: Day 1 - Day 10 of the study.

  3. Proportion of subjects using intranasal decongestant spray for nasal obstruction relief at Visit 2 (Day 3) and Visit 3 (Day 6).

    Rate of nasal decongestant spray use for symptomatic relief of nasal obstruction.

    Time frame: Day 3, Day 6 of the study.

  4. Mean daily frequency of decongestant nasal spray use at Visit 2 (Day 3) and Visit 3 (Day 6).

    The mean daily frequency of decongestant use will be calculated for each subject as the total number of administrations from the first dose of the investigational product up to the target visit, divided by the number of days in that period.

    Time frame: Day 3, Day 6 of the study.

  5. Proportion of subjects using analgesic and/or NSAID medications at Visit 2 (Day 3) and Visit 3 (Day 6).

    Rate of using analgesic and/or NSAID medications to relif symptoms of Influenza or ARVI.

    Time frame: Day 3, Day 6

  6. Mean daily frequency of analgesic and/or NSAID use at Visit 2 (Day 3) and Visit 3 (Day 6).

    The mean daily frequency of analgesic and/or NSAID use will be calculated for each subject as the total number of administrations from the first dose of the investigational product up to the target visit, divided by the number of days in that period.

    Time frame: Day 3, Day 6 of the study.

  7. Proportion of subjects with viral elimination by Visit 3 (Day 6).

    Proportion of subjects with a negative PCR test result

    Time frame: Day 6 of the study.

  8. Assessment of clinical sign severity via pharyngoscopy at Visit 2 (Day 3) and Visit 3 (Day 6).

    * Assessment of the severity of hyperemia and ridge-like thickening of the edges of the palatine arches; * Assessment of the severity of caseous-purulent plugs or liquid pus in the tonsillar lacunae; * Assessment of the severity of edema of the tonsils; * Assessment of the severity of edema of the palatine arches; * Assessment of the severity of edema of the uvula; * Assessment of the severity of edema of the posterior pharyngeal wall. Each symptom will be assessed on a 4-point severity scale, where: 0 points - no symptom; 1 point - the minimum severity of the symptom; 2 points - moderate severity of the symptom; 3 points - the maximum severity of the symptom.

    Time frame: Day 3, Day 6 of the study.

  9. Assessment of clinical sign severity via rhinoscopy at Visit 2 (Day 3) and Visit 3 (Day 6).

    * Assessment of the severity of nasal discharge * Assessment of the severity of nasal mucosal hyperemia * Assessment of the severity of nasal mucosal edema Each symptom will be assessed on a 4-point severity scale, where: 0 points - no symptom; 1 point - the minimum severity of the symptom; 2 points - moderate severity of the symptom; 3 points - the maximum severity of the symptom.

    Time frame: Day 3, Day 6 of the study.

  10. Assessment of treatment effectiveness by the Investigator on a 5-point scale at Visit 2 (Day 3) and Visit 3 (Day 6).

    A 5-point scale will be used to assess treatment effectiveness, where: 1 point - absence of clinical symptoms, 2 points - regression of the main clinical symptoms, 3 points - reduction in the severity of clinical symptoms, 4 points - lack of positive dynamics of clinical symptoms, 5 points - worsening of clinical symptoms.

    Time frame: Day 3, Day 6 of the study.

  11. Subject's assessment of treatment effectiveness on a 5-point scale at Visit 2 (Day 3) and Visit 3 (Day 6).

    To assess treatment effectiveness from the subject's perspective, a 5-point scale will be used, where: 1 point - poor, 2 points - satisfactory, 3 points - good, 4 points - very good, 5 points - excellent.

    Time frame: Day 3, Day 6 of the study.

Other outcomes

  1. Safety and Tolerability: adverse events rate

    Number and frequency of adverse events and serious adverse events.

    Time frame: Screening (Day-1), and from Day 1 to Day 10

  2. Safety and Tolerability: adverse events associated with the study drug

    Number and frequency of adverse events associated with the study drug.

    Time frame: From Day 1 to Day 10

  3. Safety and Tolerability: serious adverse events associated with the study drug

    Number and frequency of serious adverse events associated with the study drug.

    Time frame: From Day 1 to Day 10

  4. Safety and Tolerability: proportion of subjects with at least one adverse event.

    Proportion of subjects with one or more adverse events.

    Time frame: Screening (Day-1), and from Day 1 to Day 10

  5. Safety and Tolerability: treatment discontinuation

    roportion of subjects who discontinued treatment due to an adverse events.

    Time frame: From Day 1 to Day 10

  6. Safety and Tolerability: vital signs - systolic blood pressure (SBP)

    SBP, mmHg

    Time frame: Screening, Day 1, Day 3, Day 6, and Day 10 of the study.

  7. Safety and Tolerability: vital signs - diastolic blood pressure (DBP)

    DBP, mmHg

    Time frame: Screening, Day 1, Day 3, Day 6, and Day 10 of the study.

  8. Safety and Tolerability: vital signs - respiratory rate (RR)

    RR, breaths per minute

    Time frame: Screening, Day 1, Day 3, Day 6, and Day 10 of the study.

  9. Safety and Tolerability: vital signs - body temperature

    Body temperature, Celsius temperature scale

    Time frame: Screening, Day 1, Day 3, Day 6, and Day 10 of the study.

  10. Subject complaints

    Description of complaints, recieved from subject

    Time frame: Screening (Day-1), and from Day 1 to Day 10

  11. Physical examination results - cardiovascular system

    An assessment of the condition of the cardiovascular system on physical examination (normal condition or list of abnormal conditions, if any)

    Time frame: Screening, Day 1, Day 3, Day 6, and Day 10 of the study.

  12. Physical examination results - respiratory system

    An assessment of the condition of the respiratory system on physical examination (normal condition or list of abnormal conditions, if any)

    Time frame: Screening, Day 1, Day 3, Day 6, and Day 10 of the study.

  13. Physical examination results - digestive tract

    An assessment of the condition of the digestive tract on physical examination (normal condition or list of abnormal conditions, if any)

    Time frame: Screening, Day 1, Day 3, Day 6, and Day 10 of the study.

  14. Physical examination results - endocrine system

    An assessment of the condition of the endocrine system on physical examination (normal condition or list of abnormal conditions, if any)

    Time frame: Screening, Day 1, Day 3, Day 6, and Day 10 of the study.

  15. Physical examination results - musculoskeletal system

    An assessment of the condition of the endocrine system on physical examination (normal condition or list of abnormal conditions, if any)

    Time frame: Screening, Day 1, Day 3, Day 6, and Day 10 of the study.

  16. Physical examination results - nervous system

    An assessment of the condition of the nervous system on physical examination (normal condition or list of abnormal conditions, if any)

    Time frame: Screening, Day 1, Day 3, Day 6, and Day 10 of the study.

  17. Physical examination results - skin/visible mucous membranes

    An assessment of the condition of the skin/visible mucous membranes on physical examination (normal condition or list of abnormal conditions, if any)

    Time frame: Screening, Day 1, Day 3, Day 6, and Day 10 of the study.

  18. Physical examination results - genitourinary system

    An assessment of the condition of the genitourinary system on physical examination (normal condition or list of abnormal conditions, if any)

    Time frame: Screening, Day 1, Day 3, Day 6, and Day 10 of the study.

  19. Physical examination results - otorhinolaryngological organs

    An assessment of the condition of the otorhinolaryngological organs on physical examination (normal condition or list of abnormal conditions, if any)

    Time frame: Screening, Day 1, Day 3, Day 6, and Day 10 of the study.

  20. Physical examination results - organ of vision

    An assessment of the condition of the organ of vision on physical examination (normal condition or list of abnormal conditions, if any)

    Time frame: Screening, Day 1, Day 3, Day 6, and Day 10 of the study.

  21. Safety and Tolerability: 12-lead electrocardiogram (ECG) - heart rate

    12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) taken while lying down: heart rate (beats per minute)

    Time frame: Screening, Day 3, Day 6, and Day 10 of the study.

  22. Safety and Tolerability: 12-lead electrocardiogram (ECG) - PQ interval

    12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) taken while lying down: PQ interval (ms)

    Time frame: Screening, Day 3, Day 6, and Day 10 of the study.

  23. Safety and Tolerability: 12-lead electrocardiogram (ECG) - QRS complex

    12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) taken while lying down: QRS complex (ms)

    Time frame: Screening, Day 3, Day 6, and Day 10 of the study.

  24. Safety and Tolerability: 12-lead electrocardiogram (ECG) - corrected QT interval (QTc)

    12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) taken while lying down: QTc (ms)

    Time frame: Screening, Day 3, Day 6, and Day 10 of the study.

  25. Safety and Tolerability: complete blood count - hemoglobin

    Hemoglobin, g/dL

    Time frame: Screening, Day 3, Day 6, and Day 10 of the study.

  26. Safety and Tolerability: complete blood count - hematocrit

    Hematocrit, %

    Time frame: Screening, Day 3, Day 6, and Day 10 of the study.

  27. Safety and Tolerability: complete blood count - red blood cells

    Red blood cell count (cells/L)

    Time frame: Screening, Day 3, Day 6, and Day 10 of the study.

  28. Safety and Tolerability: clinical blood test - leukocyte count

    Leukocyte count (cells/L)

    Time frame: Screening, Day 3, Day 6, and Day 10 of the study.

  29. Safety and Tolerability: clinical blood test - platelet count

    Platelet count (cells/L)

    Time frame: Screening, Day 3, Day 6, and Day 10 of the study.

  30. Safety and Tolerability: clinical blood test - erythrocyte sedimentation rate

    Erythrocyte sedimentation rate (mm/h)

    Time frame: Screening, Day 3, Day 6, and Day 10 of the study.

  31. Safety and Tolerability: clinical blood test - band neutrophils

    Leukocyte formula (band neutrophils, %)

    Time frame: Screening, Day 3, Day 6, and Day 10 of the study.

  32. Safety and Tolerability: clinical blood test - segmented neutrophils

    Leukocyte formula (segmented neutrophils, %)

    Time frame: Screening, Day 3, Day 6, and Day 10 of the study.

  33. Safety and Tolerability: clinical blood test - eosinophils

    Leukocyte formula (eosinophils, %)

    Time frame: Screening, Day 3, Day 6, and Day 10 of the study.

  34. Safety and Tolerability: clinical blood test - basophils

    Leukocyte formula (basophils, %)

    Time frame: Screening, Day 3, Day 6, and Day 10 of the study.

  35. Safety and Tolerability: clinical blood test - monocytes

    Leukocyte formula (monocytes, %)

    Time frame: Screening, Day 3, Day 6, and Day 10 of the study.

  36. Safety and Tolerability: clinical blood test - lymphocyte

    eukocyte formula (lymphocytes, %)

    Time frame: Screening, Day 3, Day 6, and Day 10 of the study.

  37. Safety and Tolerability: blood chemistry - alanine transaminase

    Alanine transaminase activity (U/L)

    Time frame: Screening, Day 3, Day 6, and Day 10 of the study.

  38. Safety and Tolerability: blood chemistry - aspartate transaminase

    Aspartate transaminase activity (U/L)

    Time frame: Screening, Day 3, Day 6, and Day 10 of the study.

  39. Safety and Tolerability: blood chemistry - bilirubin

    Total bilirubin concentration (micromol/L)

    Time frame: Screening, Day 3, Day 6, and Day 10 of the study.

  40. Safety and Tolerability: blood chemistry - glucose

    Glucose concentration (mmol/L)

    Time frame: Screening, Day 3, Day 6, and Day 10 of the study.

  41. Safety and Tolerability: blood chemistry - total protein

    Total protein in blood serum (g/L)

    Time frame: Screening, Day 3, Day 6, and Day 10 of the study.

  42. Safety and Tolerability: blood chemistry - creatinine

    Creatinine concentration (micromol/L)

    Time frame: Screening, Day 3, Day 6, and Day 10 of the study.

  43. Safety and Tolerability: blood chemistry - urea

    Urea in blood serum (mmol/L)

    Time frame: Screening, Day 3, Day 6, and Day 10 of the study.

  44. C-reactive protein (CRP)

    Serum C-reactive protein (mg/L))

    Time frame: Screening, Day 3, Day 6, and Day 10 of the study.

  45. Safety and Tolerability: urinalysis - pH

    pH of the urine

    Time frame: Screening, Day 3, Day 6, and Day 10 of the study.

  46. Safety and Tolerability: urinalysis - specific gravity

    Specific gravity of the urine

    Time frame: Screening, Day 3, Day 6, and Day 10 of the study.

  47. Safety and Tolerability: urinalysis - protein

    Protein concentration (g/L)

    Time frame: Screening, Day 3, Day 6, and Day 10 of the study.

  48. Safety and Tolerability: urinalysis - glucose

    Glucose concentration (mmol/L)

    Time frame: Screening, Day 3, Day 6, and Day 10 of the study.

  49. Safety and Tolerability: urinalysis - red blood cells

    Red blood cell content (number in sight)

    Time frame: Screening, Day 3, Day 6, and Day 10 of the study.

  50. Safety and Tolerability: urinalysis - white blood cells

    White blood cell content (number in sight)

    Time frame: Screening, Day 3, Day 6, and Day 10 of the study.

07

Study locations

11 of 11 sites recruiting
  • Regional Budgetary Healthcare Institution "Kuvaev Ivanovo Clinical Hospital"
    Ivanovo, 153025, Russia
    Recruiting
  • Federal State Budgetary Educational Institution of Higher Education "Kirov State Medical University" of the Ministry of Healthcare of the Russian Federation
    Kirov, 610027, Russia
    Recruiting
  • "Medical and Diagnostic Center Veris" LLC
    Kirov, 610046, Russia
    Recruiting
  • State Budgetary Healthcare Institution of the City of Moscow "Consultative and Diagnostic Polyclinic № 121 of the Moscow City Department of Healthcare"
    Moscow, 117042, Russia
    Recruiting
  • Unimed-C Jsc
    Moscow, 119571, Russia
    Recruiting
  • "Professor's Clinic" LLC
    Perm, 614070, Russia
    Recruiting
  • "Aurora MedFort" LLC
    Saint Petersburg, 194156, Russia
    Recruiting
  • "Eosmed" LLC
    Saint Petersburg, 195197, Russia
    Recruiting
  • "OrCli Hospital" LLC
    Saint Petersburg, 199178, Russia
    Recruiting
  • Federal State Budgetary Educational Institution of Higher Education "National Research Ogarev Mordovia State University"
    Saransk, 430005, Russia
    Recruiting
    • Natalya Selezneva, MD, PhD · Contactnata_rm@mail.ru · + 7 (8342) 33-34-09
  • "DNA Research Center" LLC
    Saratov, 410019, Russia
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Dec 2027, 26 months after the start.

Of 86 industry-sponsored phase 2 interventional studies under Influenza, Human, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's planned 26 months is above that.

Counting every sponsor, half of 122 studies reached it within 10 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2026
First posted
Feb 19, 2026
StartActual
Oct 24, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Feb 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07420985
Lead sponsor
Valenta Pharm JSC
Responsible party
Sponsor
First posted
Feb 19, 2026
Start date
Oct 24, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Feb 19, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion